When was Epicrispr Bio founded?

Epicrispr Bio was founded in 2018 and raised its 1st funding round 7 years after it was founded.

Where is Epicrispr Bio located?

Epicrispr Bio is headquartered in San Francisco, United States.

Who is the current CEO of Epicrispr Bio?

Amber Salzman of Epicrispr Bio.

How many employees does Epicrispr Bio have?

As of Sep 30, 2026, the latest employee count at Epicrispr Bio is 53.

Is Epicrispr Bio a funded company?

Epicrispr Bio is a funded company, having raised a total of $245M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Mar 27, 2025.

When was the latest funding round of Epicrispr Bio?

Epicrispr Bio's latest funding was a $***** Grant (prize money) round on Oct 19, 2026, with participation from 1 investor.

Where does Epicrispr Bio rank among its competitors?

Epicrispr Bio ranks 64th amongst 975 active competitors, of which 328 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Epicrispr Bio, which secured $177M in Aug, 2026.

Who are the top competitors of Epicrispr Bio?

Epicrispr Bio's top competitors include BridgeBio, Alnylam and Biogen. Among them, Epicrispr Bio secured the most recent funding round in October, 2026.

Epicrispr Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for multiple diseases. It offers gene therapies using ultracompact Cas proteins which modulate gene expression without cutting DNA. The company's platform leverages the power of CRISPR/Cas9 gene editing to target specific genes and achieve therapeutic outcomes. The pipeline includes EPI-321 for facioscapulohumeral muscular dystrophy, EPI-221, EPI-224 for genetic disorder, EPI 114 and EPI 111 for petinas pigmentosa.

Website: epicrispr.com
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Series C

Total Funding

$245M in 3 rounds

Latest Funding Round

Grant (prize money), Oct 19, 2026, $*****

Investors

Ally Bridge Group & 11 more

Ranked

64^th among 975 active competitors

Employee Count

53 as on Sep 30, 2026

Similar Companies

BridgeBio & 1154 more

View Epicrispr Bio's full profile

Epicrispr Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
EPICRISPR BIOTECHNOLOGIES, INC CIN: 824177431 , United States, Active	Dec 31, 1999	-	38 (As on Dec 31, 2024)	-

Epicrispr Bio has raised a total funding of $245M over 3 rounds. Its first funding round was on Mar 27, 2025. Its latest funding round was a Grant (prize money) round on Oct 19, 2026 for $*****. 1 investor participated in its latest round. Epicrispr Bio has 12 institutional investors.

Here is the list of recent funding rounds of Epicrispr Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 19, 2026	7604445	Grant (prize money)	4837561	9465239	5775152	9278302
May 04, 2026	6018159	Series C	1724694	7850989	2548863	Janus Henderson Investors & 7 more
Mar 27, 2025	5595088	Series B	2845355	2868532	Ally Bridge Group	Solve FSHD

Access funding benchmarks and valuations. Sign up today!

View details of Epicrispr Bio's funding rounds and investors

The founders of Epicrispr Bio is Lei Stanley Qi. Amber Salzman is the CEO of Epicrispr Bio.

Here are the details of Epicrispr Bio's key team members:

Lei Stanley Qi: Founder of Epicrispr Bio and founder of 1 other company.
Amber Salzman: CEO of Epicrispr Bio.
Contact Info: 1 email address

View details of Epicrispr Bio's Founder profiles and Board Members

Epicrispr Bio's employee count trend

Epicrispr Bio has 53 employees as of Sep 26. Here is Epicrispr Bio's employee count trend over the years:

Uncover Epicrispr Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Epicrispr Bio include BridgeBio, Alnylam and Biogen. Here is the list of Top 10 competitors of Epicrispr Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	70/100
8th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	71/100
9th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
10th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
64th	Epicrispr Bio 2018, San Francisco (United States), Series C	Developer of therapeutics for multiple disease	$245M	Fidelity Investments, Janus Henderson Investors ... & 10 others	62/100